Literature DB >> 16141458

Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management.

Ewout J Hoorn1, Jan Lindemans, Robert Zietse.   

Abstract

BACKGROUND: Although hyponatraemia [plasma sodium (PNa)<136 mmol/l] frequently develops in hospital, risk factors for hospital-acquired hyponatraemia remain unclear.
METHODS: Patients who presented with severe hyponatraemia (PNa<or=125 mmol/l) were compared with patients with hospital-acquired severe hyponatraemia in a 3 month hospital-wide cohort study.
RESULTS: Thirty-eight patients had severe hyponatraemia on admission (PNa 121+/-4 mmol/l), whereas 36 patients had hospital-acquired severe hyponatraemia (PNa 133+/-5-->122+/-4 mmol/l). In hospital-acquired hyponatraemia, treatment started significantly later (1.0+/-2.6 vs 9.8+/-10.6 days, P<0.001) and the duration of hospitalization was longer (18.2+/-11.5 vs 30.7+/-23.4 days, P=0.01). The correction of PNa in hospital-acquired hyponatraemia was slower after both 24 h (6+/-4 vs 4+/-4 mmol/l, P=0.009) and 48 h (10+/-6 mmol/l vs 6+/-5 mmol/l, P=0.001) of treatment. Nineteen patients (26%) from both groups were not treated for hyponatraemia and this was associated with a higher mortality rate (seven out of 19 vs seven out of 55, P=0.04). Factors that contributed to hospital-acquired hyponatraemia included: thiazide diuretics (none out of 38 vs eight out of 36, P=0.002), drugs stimulating antidiuretic hormone (two out of 38 vs eight out of 36, P=0.04), surgery (none out of 38 vs 10 out of 36, P<0.001) and hypotonic intravenous fluids (one out of 38 vs eight out of 36, P=0.01). Symptomatic hyponatraemia was present in 27 patients (36%), and 14 patients died (19%).
CONCLUSIONS: The development of severe hyponatraemia in hospitalized patients was associated with treatment-related factors and inadequate management. Early recognition of risk factors and expedited therapy may make hospital-acquired severe hyponatraemia more preventable.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16141458     DOI: 10.1093/ndt/gfi082

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  73 in total

1.  Effect of hypoxia on the cerebral adaptation to acute hyponatremia in experimental animals.

Authors:  Howard Trachtman
Journal:  Pediatr Nephrol       Date:  2006-10-17       Impact factor: 3.714

2.  Variation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepressants.

Authors:  Sonja Kwadijk-de Gijsel; Monique J Bijl; Loes E Visser; Ron H N van Schaik; Albert Hofman; Arnold G Vulto; Teun van Gelder; Bruno H Ch Stricker
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

Review 3.  Hyponatraemia - presentations and management.

Authors:  Rosemary Dineen; Christopher J Thompson; Mark Sherlock
Journal:  Clin Med (Lond)       Date:  2017-06       Impact factor: 2.659

4.  Progressive kidney disease may not alter the association of hyponatremia with mortality.

Authors:  Ladan Golestaneh; Joel Neugarten; Frederick Kaskel; Aileen P McGinn
Journal:  Clin Exp Nephrol       Date:  2018-02-02       Impact factor: 2.801

5.  Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.

Authors:  Michael J Roy; Keith A Erdman; Anura T Abeyratne; Lisa C Plumb; Kenneth Lasseter; Dennis S Riff; James J Keirns
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

6.  Management of hyponatremia in various clinical situations.

Authors:  Michael L Moritz; Juan C Ayus
Journal:  Curr Treat Options Neurol       Date:  2014-09       Impact factor: 3.598

7.  SIADH and hyponatraemia: foreword.

Authors:  Donal O'Donoghue; Anu Trehan
Journal:  NDT Plus       Date:  2009-11

8.  Efficacy and safety of two different tolvaptan doses in the treatment of hyponatremia in the Emergency Department.

Authors:  Luigi Mario Castello; Marco Baldrighi; Alice Panizza; Ettore Bartoli; Gian Carlo Avanzi
Journal:  Intern Emerg Med       Date:  2016-07-21       Impact factor: 3.397

Review 9.  New aspects in the pathogenesis, prevention, and treatment of hyponatremic encephalopathy in children.

Authors:  Michael L Moritz; Juan Carlos Ayus
Journal:  Pediatr Nephrol       Date:  2009-11-06       Impact factor: 3.714

10.  SIADH and hyponatraemia: why does it matter?

Authors:  Ewout J Hoorn; Nils van der Lubbe; Robert Zietse
Journal:  NDT Plus       Date:  2009-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.